Jeremy Force

2.1k total citations
49 papers, 1.4k citations indexed

About

Jeremy Force is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jeremy Force has authored 49 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 21 papers in Cancer Research. Recurrent topics in Jeremy Force's work include Breast Cancer Treatment Studies (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Advanced Breast Cancer Therapies (9 papers). Jeremy Force is often cited by papers focused on Breast Cancer Treatment Studies (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Advanced Breast Cancer Therapies (9 papers). Jeremy Force collaborates with scholars based in United States, United Kingdom and Malaysia. Jeremy Force's co-authors include Judah Folkman, John V. Heymach, Zachary C. Hartman, Li-Chung Tsao, Terry Hyslop, Paul Beaudry, Jennifer K. Plichta, Rachel A. Greenup, Laura H. Rosenberger and Oluwadamilola M. Fayanju and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Surgery.

In The Last Decade

Jeremy Force

45 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeremy Force United States	19	653	616	588	273	215	49	1.4k
Akihiko Osaki Japan	23	529 0.8×	747 1.2×	528 0.9×	283 1.0×	155 0.7×	116	1.7k
Débora De Melo Gagliato Brazil	14	426 0.7×	953 1.5×	501 0.9×	528 1.9×	144 0.7×	36	1.5k
Giorgia Migliardi Italy	18	515 0.8×	719 1.2×	277 0.5×	352 1.3×	180 0.8×	28	1.3k
Valentina Gambardella Spain	18	474 0.7×	755 1.2×	485 0.8×	471 1.7×	236 1.1×	85	1.5k
Amy P. Sing United States	16	500 0.8×	1.4k 2.2×	745 1.3×	435 1.6×	289 1.3×	32	1.9k
Ernesto Wasserman United States	17	418 0.6×	812 1.3×	377 0.6×	358 1.3×	114 0.5×	35	1.2k
Tae-You Kim South Korea	24	678 1.0×	689 1.1×	277 0.5×	420 1.5×	299 1.4×	48	1.5k
Raija Ristamäki Finland	21	535 0.8×	760 1.2×	307 0.5×	230 0.8×	226 1.1×	52	1.3k
Maja J.A. de Jonge Netherlands	19	865 1.3×	848 1.4×	259 0.4×	420 1.5×	195 0.9×	40	1.6k
Séverine Guiu France	24	399 0.6×	1.1k 1.9×	751 1.3×	464 1.7×	168 0.8×	78	1.9k

Countries citing papers authored by Jeremy Force

Since Specialization

Citations

This map shows the geographic impact of Jeremy Force's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy Force with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy Force more than expected).

Fields of papers citing papers by Jeremy Force

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremy Force. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy Force. The network helps show where Jeremy Force may publish in the future.

Co-authorship network of co-authors of Jeremy Force

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremy Force. A scholar is included among the top collaborators of Jeremy Force based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremy Force. Jeremy Force is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McCourt, Carolyn K., Zihan Wei, Kevin Kalinsky, et al.. (2025). Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K. Clinical Cancer Research. 31(23). 4912–4919. 2 indexed citations

Sag, Alan A., James Ronald, Isaac O. Oyediran, et al.. (2025). Cryoablation of bone, soft tissue, and nerve in the setting of uninterrupted systemic cancer therapies. Clinical Imaging. 121. 110467–110467.

Berdunov, Vladislav, et al.. (2023). The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective. Journal of Medical Economics. 26(1). 973–990. 1 indexed citations

Nusser, Kevin D., Kristen L. Jones, Clare Keddy, et al.. (2023). Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. EMBO Molecular Medicine. 15(10). e17367–e17367. 4 indexed citations

Force, Jeremy, Joyce O’Shaughnessy, Sara A. Hurvitz, et al.. (2023). Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.. Journal of Clinical Oncology. 41(16_suppl). 603–603. 1 indexed citations

Morse, Michael A., Erika J. Crosby, Jeremy Force, et al.. (2023). Clinical trials of self-replicating RNA-based cancer vaccines. Cancer Gene Therapy. 30(6). 803–811. 29 indexed citations

Qin, Xiaodi, Brock J. McKinney, Jeremy Force, et al.. (2021). APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses. Cancer Immunology Research. 10(1). 70–86. 28 indexed citations

Lee, HJ, et al.. (2021). 253P Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) + fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC). Annals of Oncology. 32. S470–S470. 4 indexed citations

Drusbosky, Leylah, Mehmet Asım Bilen, Georges Azzi, et al.. (2021). Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.. Journal of Clinical Oncology. 39(15_suppl). 3040–3040. 13 indexed citations

10.

Fayanju, Oluwadamilola M., Yi Ren, Rachel A. Greenup, et al.. (2020). Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Research and Treatment. 180(1). 207–217. 21 indexed citations

11.

Lin, Chao‐Chieh, Nathaniel W. Mabe, Yi-Tzu Lin, et al.. (2020). RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence. Cell Death and Differentiation. 27(7). 2234–2247. 45 indexed citations

12.

Plichta, Jennifer K., Yi Ren, Samantha M. Thomas, et al.. (2020). Surgery for Men with Breast Cancer: Do the Same Data Still Apply?. Annals of Surgical Oncology. 27(12). 4720–4729. 7 indexed citations

13.

Fayanju, Oluwadamilola M., Yi Ren, Gita Suneja, et al.. (2019). Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis. International Journal of Radiation Oncology*Biology*Physics. 106(2). 377–389. 12 indexed citations

14.

Force, Jeremy, et al.. (2019). Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading. Current Treatment Options in Oncology. 20(4). 35–35. 43 indexed citations

15.

Ong, Cecilia T., Samantha M. Thomas, Rachel A. Greenup, et al.. (2018). Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Annals of Surgical Oncology. 25(8). 2249–2260. 75 indexed citations

16.

Force, Jeremy, Lynn Howie, Sara Abbott, et al.. (2018). Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. Clinical Breast Cancer. 18(5). 410–417. 22 indexed citations

17.

Fayanju, Oluwadamilola M., Yi Ren, Samantha M. Thomas, et al.. (2018). The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT). Annals of Surgery. 268(4). 591–601. 147 indexed citations

18.

Kelly, Ronan J., Arun Rajan, Jeremy Force, et al.. (2011). Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib. Clinical Cancer Research. 17(5). 1190–1199. 58 indexed citations

19.

Force, Jeremy, Arun Rajan, Eva Dombi, Seth M. Steinberg, & Giuseppe Giaccone. (2011). Assessment of Objective Responses Using Volumetric Evaluation in Advanced Thymic Malignancies and Metastatic Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(7). 1267–1273. 15 indexed citations

20.

Kelly, Ronan J., Jeremy Force, C.W. Keen, et al.. (2010). Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S).. Journal of Clinical Oncology. 28(15_suppl). 7626–7626. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact